🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

254 results for “AstraZeneca” Clear

  1. DEXTROMETHORPHANE ELERTE 1,5 mg/ml, sirop, AZD3470, AZD3470, Midazolam-ratiopharm® 2 mg/ml orale Lösung

    AstraZeneca AB

    Advanced/metastatic solid tumors that are MTAP deficient.

    phase 1 small molecule active

    1 trial

  2. Koselugo 25 mg hard capsules, Koselugo 10 mg hard capsules

    AstraZeneca AB

    Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN)

    phase 1 small molecule active

    1 trial

  3. LENVIMA 4 mg hard capsules, volrustomig, Kisplyx 10 mg hard capsules, Kisplyx 4 mg hard capsules, LENVIMA 10 mg hard capsules

    AstraZeneca AB

    Advanced Renal Cell Carcinoma

    phase 1 small molecule active

    1 trial

  4. Lynparza 100 mg film-coated tablets, AZD2281, AZD2281, AZD2281

    AstraZeneca AB

    solid tumors

    phase 1 small molecule active

    1 trial

  5. MYCOPHENOLATE MOFETIL, INFLIXIMAB, Rilvegostomig, Rilvegostomig, volrustomig, CARBOPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., Datopotamab deruxtecan, AZD7789

    AstraZeneca AB

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 1 small molecule active

    1 trial

  6. PET study of changes in [11C]AZ14132516 uptake following administration of multiple AZD7798 doses to patients with Crohn’s disease.

    AstraZeneca AB

    Crohn's disease

    phase 1 other active

    1 trial

  7. Phase 1 Study of AZD9833 Alone or in Combination in Women with Advanced Breast Cancer

    AstraZeneca AB

    "Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer"

    phase 1 other active

    1 trial

  8. Phase Ib Randomised, Placebo-controlled, Double-blind, Multicentre Study to Assess the Effects and Safety of AZD5462 on top of Dapagliflozin in Participants with Heart Failure and Moderate Renal Impairment

    AstraZeneca AB

    Moderate Renal Impairment, Heart Failure

    phase 1 other active

    1 trial

  9. TRUQAP 200 mg film-coated tablets, Faslodex 250 mg solution for injection., TRUQAP 160 mg film-coated tablets, PACLITAXEL, IMFINZI 50 mg/mL concentrate for solution for infusion., Capecitabine Accord 500 mg film-coated tablets, Capecitabine Accord 150 mg film-coated tablets, DS-8201a, Arimidex® 1 mg film-coated tablets

    AstraZeneca AB

    Metastatic Breast Cancer

    phase 1 small molecule active

    1 trial

  10. Calquence 100 mg film-coated tablets, Calquence 100 mg film-coated tablets

    AstraZeneca AB

    Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment

    approved small molecule active

    1 trial

  11. DS-8201a

    AstraZeneca AB

    Treatment of patients with HER2-positive breast cancer with or without brain metastasis

    approved small molecule active

    1 trial

  12. IMFINZI 50 mg/mL concentrate for solution for infusion., Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets

    AstraZeneca

    Advanced or recurrent endometrial cancer

    approved small molecule active

    1 trial

  13. Placebo for benralizumab for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (apfs) for subcutaneous injection., Fasenra 30 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Severe eosinophilic asthma

    approved small molecule active

    1 trial

  14. The placebo MDI is formulated as a suspension of spray-dried porous particles (consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC] and calcium chloride) in a hydrofluoroalkane propellant (HFA-134a). The placebo MDI uses the same excipients as active product but with absence of the active pharmaceutical ingredient (API)., Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources